Cwm LLC Buys 54,286 Shares of Abbott Laboratories $ABT

Key Points

• Cwm LLC raised its stake in Abbott by 19.9%, buying 54,286 shares to hold 327,276 shares worth about $41.0 million per its latest SEC filing.
• Abbott slightly beat Q1 expectations (revenue $11.16B; adjusted EPS $1.15) but cut near‑term guidance—about a $0.20/share dilution tied to the Exact Sciences acquisition—which triggered selling pressure despite underlying diagnostics and device strength.
• The company announced a quarterly dividend of $0.63 ($2.52 annualized, ~2.7% yield) and retains a consensus analyst stance of a Moderate Buy with a $134 price target.

Cwm LLC raised its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 19.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 327,276 shares of the healthcare product maker's stock after purchasing an additional 54,286 shares during the period. Cwm LLC's holdings in Abbott Laboratories were worth $41,004,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Harbor Capital Advisors Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $27,000. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories in the third quarter worth about $29,000. Guerra Advisors Inc bought a new position in shares of Abbott Laboratories in the third quarter worth about $31,000. Bridge Generations Wealth Management LLC bought a new position in shares of Abbott Laboratories in the third quarter worth about $33,000. Finally, Copia Wealth Management bought a new position in shares of Abbott Laboratories in the third quarter worth about $38,000. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $95.08 on Friday. The stock has a 50 day moving average of $108.17 and a 200 day moving average of $119.01. Abbott Laboratories has a 12 month low of $93.92 and a 12 month high of $139.06. The firm has a market cap of $165.59 billion, a PE ratio of 25.56, a PEG ratio of 1.62 and a beta of 0.79. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the prior year, the business posted $1.09 earnings per share. The company's quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. Abbott Laboratories's dividend payout ratio is 67.74%.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Q1 revenue and adjusted EPS roughly met/beat Street expectations (revenue $11.16B; adj. EPS $1.15), helped by medical-device and cancer‑diagnostics strength — this supports near‑term topline resilience. Abbott first-quarter results beat on cancer diagnostics, medical device strength
• Positive Sentiment: RBC Capital reaffirmed its Buy rating on ABT, which can provide dealer/analyst support amid the selloff. RBC Capital Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
• Positive Sentiment: Insiders added shares recently (about $3.1M), a small but constructive signal of management confidence. Abbott Laboratories Insiders Added US$3.10m Of Stock To Their Holdings
• Neutral Sentiment: Management says the Exact Sciences deal positions Abbott in high‑growth oncology diagnostics (longer‑term strategic benefit), though that was cited as the near‑term EPS drag. Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
• Negative Sentiment: Abbott cut FY‑2026 and Q2 guidance to reflect roughly $0.20/share dilution from the Exact Sciences acquisition and issued softer Q2 EPS guidance than consensus — the guidance cut is the main driver of investor selling. Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales
• Negative Sentiment: Margin compression and weakness in the Nutrition segment (and a mild flu season that reduced testing/consumables) weighed on profitability expectations and investor sentiment. Abbott Stock Falls Despite Q1 Earnings & Revenue Beat
• Negative Sentiment: Market reaction included downgrades in quantitative rankings and attention from health‑care ETFs, amplifying selling pressure beyond fundamental headlines. Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings
• Negative Sentiment: Potential legal/market risk from an Illinois NEC verdict was flagged as a new liability item for shareholders to monitor. What Abbott Laboratories (ABT)'s First Illinois NEC Verdict Means For Shareholders

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP John A. Jr. Mccoy sold 585 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the sale, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company's stock.

Analyst Ratings Changes

ABT has been the subject of a number of recent analyst reports. Citigroup dropped their price objective on Abbott Laboratories from $140.00 to $136.00 and set a "buy" rating for the company in a research note on Wednesday, March 11th. Royal Bank Of Canada dropped their price target on Abbott Laboratories from $147.00 to $135.00 and set an "outperform" rating for the company in a research note on Friday, January 23rd. Piper Sandler dropped their price target on Abbott Laboratories from $150.00 to $135.00 and set an "overweight" rating for the company in a research note on Friday, January 23rd. Oppenheimer dropped their price target on Abbott Laboratories from $140.00 to $132.00 and set an "outperform" rating for the company in a research note on Friday, January 23rd. Finally, Barclays increased their price target on Abbott Laboratories from $142.00 to $144.00 and gave the company an "overweight" rating in a research note on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $134.00.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.